Colony-stimulating factors (CSFs) are secreted glycoproteins that bind to receptor proteins on the surfaces of committed progenitors[1] in the bone marrow, thereby activating intracellular signaling pathways that can cause the cells to proliferate and differentiate into a specific kind of blood cell (usually white blood cells. For red blood cell formation, see erythropoietin).
They may be synthesized and administered exogenously. However, such molecules can at a latter stage be detected, since they differ slightly from the endogenous ones in, e.g., features of post-translational modification.
Etymology
The name "colony-stimulating factors" comes from the method by which they were discovered.
Hematopoietic stem cells were cultured (see cell culture) on a so-called semisolid matrix, which prevents cells from moving around, so that, if a single cell starts proliferating, all of the cells derived from it will remain clustered around the spot in the matrix where the first cell was originally located. These are referred to as "colonies". Therefore, it was possible to add various substances to cultures of hemopoietic stem cells and then examine which kinds of colonies (if any) were "stimulated" by them.
The substance that was found to stimulate formation of colonies of macrophages, for instance, was called macrophage colony-stimulating factor, for granulocytes, granulocyte colony-stimulating factor, and so on.
Mechanism
The colony-stimulating factors are soluble (permeable), in contrast to other, membrane-bound substances of the hematopoietic microenvironment. This is sometimes used as the definition of CSFs. They transduce by paracrine, endocrine, or autocrine signaling.
Examples
Colony-stimulating factors include:
Clinical uses
- Bone marrow stimulation
- Stem cell mobilization
References
- ^ Kumar, Vinay; Abbas, Abul K.; Aster, Jon C.; Turner, Jerrold R.; Perkins, James A.; Robbins, Stanley L.; Cotran, Ramzi S., eds. (2021). Robbins & Cotran Pathologic Basis of Disease (10th ed.). Philadelphia, PA: Elsevier. p. 584. ISBN 978-0-323-53113-9.
- Alberts, Bruce; et al. (2002). Molecular Biology of the Cell (4th ed.). New York, NY: Garland Science. ISBN 0-8153-4072-9.
External links
|
|---|
| By family | |
|---|
By function/ cell | |
|---|
|
|---|
| Angiopoietin |
- Kinase inhibitors: Altiratinib
- CE-245677
- Rebastinib
- Antibodies: Evinacumab (against angiopoietin 3)
- Nesvacumab (against angiopoietin 2)
|
|---|
| CNTF | |
|---|
| EGF (ErbB) | |
|---|
| FGF | | FGFR1 |
- Agonists: Ersofermin
- FGF (1, 2 (bFGF), 3, 4, 5, 6, 8, 10 (KGF2), 20)
- Repifermin
- Selpercatinib
- Trafermin
- Velafermin
|
|---|
| FGFR2 |
- Agonists: Ersofermin
- FGF (1, 2 (bFGF), 3, 4, 5, 6, 7 (KGF), 8, 9, 10 (KGF2), 17, 18, 22)
- Palifermin
- Repifermin
- Selpercatinib
- Sprifermin
- Trafermin
- Antibodies: Aprutumab
- Aprutumab ixadotin
- Kinase inhibitors: Infigratinib
|
|---|
| FGFR3 | |
|---|
| FGFR4 |
- Agonists: Ersofermin
- FGF (1, 2 (bFGF), 4, 6, 8, 9, 19)
- Trafermin
|
|---|
| Unsorted | |
|---|
|
|---|
| HGF (c-Met) |
- Kinase inhibitors: Altiratinib
- AM7
- AMG-458
- Amuvatinib
- BMS-777607
- Cabozantinib
- Capmatinib
- Crizotinib
- Foretinib
- Golvatinib
- INCB28060
- JNJ-38877605
- K252a
- MK-2461
- PF-04217903
- PF-2341066
- PHA-665752
- SU-11274
- Tivantinib
- Volitinib
- Antibodies: Emibetuzumab
- Ficlatuzumab
- Flanvotumab
- Onartuzumab
- Rilotumumab
- Telisotuzumab
- Telisotuzumab vedotin
|
|---|
| IGF | | IGF-1 |
- Kinase inhibitors: BMS-754807
- Linsitinib
- NVP-ADW742
- NVP-AEW541
- OSl-906
- Antibodies: AVE-1642
- Cixutumumab
- Dalotuzumab
- Figitumumab
- Ganitumab
- Robatumumab
- R1507
- Teprotumumab
- Xentuzumab (against IGF-1 and IGF-2)
|
|---|
| IGF-2 |
- Antibodies: Dusigitumab
- Xentuzumab (against IGF-1 and IGF-2)
|
|---|
| Others |
- Binding proteins: IGFBP (1, 2, 3, 4, 5, 6, 7)
- Cleavage products/derivatives with unknown target: Glypromate (GPE, (1-3)IGF-1)
- Trofinetide
|
|---|
|
|---|
| LNGF (p75NTR) |
- Antibodies: Against NGF: ABT-110 (PG110)
- ASP-6294
- Fasinumab
- Frunevetmab
- Fulranumab
- MEDI-578
- Ranevetmab
- Tanezumab
- Aptamers: Against NGF: RBM-004
- Decoy receptors: LEVI-04 (p75NTR-Fc)
|
|---|
| PDGF | |
|---|
| RET (GFL) | | GFRα1 | |
|---|
| GFRα2 |
- Agonists: Neurturin (NRTN)
|
|---|
| GFRα3 | |
|---|
| GFRα4 |
- Agonists: Persephin (PSPN)
|
|---|
| Unsorted |
- Kinase inhibitors: Agerafenib
|
|---|
|
|---|
| SCF (c-Kit) | |
|---|
| TGFβ | |
|---|
| Trk | | TrkA |
- Negative allosteric modulators: VM-902A
- Antibodies: Against TrkA: GBR-900; Against NGF: ABT-110 (PG110)
- ASP-6294
- Fasinumab
- Frunevetmab
- Fulranumab
- MEDI-578
- Ranevetmab
- Tanezumab
- Aptamers: Against NGF: RBM-004
- Decoy receptors: ReN-1820 (TrkAd5)
|
|---|
| TrkB |
- Agonists: 3,7-DHF
- 3,7,8,2'-THF
- 4'-DMA-7,8-DHF
- 7,3'-DHF
- 7,8-DHF
- 7,8,2'-THF
- 7,8,3'-THF
- Amitriptyline
- BDNF
- BNN-20
- Deoxygedunin
- Deprenyl
- Diosmetin
- DMAQ-B1
- HIOC
- LM22A-4
- N-Acetylserotonin
- NT-3
- NT-4
- Norwogonin (5,7,8-THF)
- R7
- R13
- TDP6
|
|---|
| TrkC | |
|---|
|
|---|
| VEGF |
- Allosteric modulators: Cyclotraxin B
|
|---|
| Others |
- Additional growth factors: Adrenomedullin
- (see here instead)
- Connective tissue growth factor (CTGF)
- Ephrins (A1, A2, A3, A4, A5, B1, B2, B3)
- Erythropoietin (see here instead)
- Glucose-6-phosphate isomerase (GPI; PGI, PHI, AMF)
- Glia maturation factor (GMF)
- Hepatoma-derived growth factor (HDGF)
- Interleukins/T-cell growth factors (see here instead)
- Leukemia inhibitory factor (LIF)
- Macrophage-stimulating protein (MSP; HLP, HGFLP)
- Midkine (NEGF2)
- Migration-stimulating factor (MSF; PRG4)
- Oncomodulin
- Pituitary adenylate cyclase-activating peptide (PACAP)
- Pleiotrophin
- Renalase
- Thrombopoietin (see here instead)
- Wnt signaling proteins
- Additional growth factor receptor modulators: Cerebrolysin (neurotrophin mixture)
|
|---|
|
|---|
| Chemokine | |
|---|
| CSF | |
|---|
| Interferon | | IFNAR (α/β, I) |
- Agonists: Albinterferon
- Interferon alpha (interferon alfa, IFN-α)
- Interferon alfa (IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA21)
- Interferon alfa 2a
- Interferon alfa 2b
- Interferon alfa n1
- Interferon alfacon-1
- Interferon alpha-n3
- Interferon beta (IFN-β) (IFNB1, IFNB3)
- Interferon beta 1a
- Interferon beta 1b
- Interferon kappa (IFN-ε/κ/τ/ζ, IFNK)
- Interferon omega (IFN-ω, IFNW1)
- Peginterferon alfa-2a
- Peginterferon alfa-2b
- Antibodies: Anifrolumab
- Faralimomab
- MEDI-545
- Rontalizumab
- Sifalimumab
- Decoy receptors: Bifarcept
|
|---|
| IFNGR (γ, II) | |
|---|
| IFNLR (λ, III) |
- See IL-28R (IFNLR) here instead.
|
|---|
|
|---|
| Interleukin | |
|---|
| TGFβ | |
|---|
| TNF | |
|---|
| Others | |
|---|